FAQ on Lantern Pharma's Breakthrough in DLBCL Treatment with LP-284

What is LP-284 and how does it work?

LP-284 is a next-generation acylfulvene developed using Lantern Pharma’s RADR(R) AI platform, designed with a synthetic lethal mechanism to target and treat refractory lymphomas, including aggressive forms of DLBCL.

Why is the complete metabolic response in the Phase 1 trial significant?

This response is significant because it occurred in a heavily pretreated patient who had failed three prior regimens, including CAR-T and bispecific antibody therapy, highlighting LP-284’s potential as a paradigm-shifting therapy for refractory lymphomas.

How does Lantern Pharma’s RADR(R) AI platform contribute to drug development?

The RADR(R) AI platform leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to accelerate the discovery and development of oncology drugs, reducing the timeline and cost significantly.

What are the implications of this development for the B-cell cancer market?

This development supports the accelerated development of LP-284 and its potential to address unmet needs in the $4 billion global B-cell cancer market, offering hope for patients with refractory lymphomas.

Where can I find more information about Lantern Pharma and its trials?

More information is available in the company’s newsroom at https://ibn.fm/LTRN and the full press release can be viewed at https://ibn.fm/TCGHH.

Who is involved in the development of LP-284?

Lantern Pharma, with input from world-class scientific advisors and collaborators, is developing LP-284 using its proprietary AI and machine learning platform, RADR(R), to target refractory lymphomas.

What makes LP-284 different from other treatments for DLBCL?

LP-284’s synthetic lethal mechanism and development via AI-driven insights differentiate it from traditional treatments, offering a novel approach to targeting aggressive and refractory forms of DLBCL.

How long does it take for Lantern Pharma to advance a drug program from AI insights to clinical trials?

On average, Lantern Pharma advances its newly developed drug programs from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program.